Related Experiment Video

Updated: Jul 19, 2026

Visualization and Analysis of Blood Flow and Oxygen Consumption in Hepatic Microcirculation: Application to an Acute Hepatitis Model
10:40

Visualization and Analysis of Blood Flow and Oxygen Consumption in Hepatic Microcirculation: Application to an Acute Hepatitis Model

Published on: August 4, 2012

The close participation of ET-1 and NO in human hepatic hemodynamics

Norio Noguchi1, Kenichi Teramoto, Takanori Ochiai

  • 1Department of Hepatobiliarypancreatic Surgery, Tokyo Medical and Dental University, 1-5-45 Yushima Bunnkyo ku, Tokyo 113-8519, Japan.

Hepatology Research : the Official Journal of the Japan Society of Hepatology
|October 10, 2006
PubMed

Insights

Endothelin-1 (ET-1) in portal blood is linked to hepatic blood flow. The ratio of nitric oxide (NOx) to ET-1 better indicates blood flow than either molecule alone.

Area of Science:

  • Hepatology
  • Vascular Biology
  • Clinical Research

Background:

  • Nitric oxide (NO) and endothelin-1 (ET-1) are implicated in hepatic circulation.
  • Previous clinical studies evaluating their roles in hepatic circulation are lacking.

Purpose of the Study:

  • To investigate the clinical significance of nitric oxide (NO) and endothelin-1 (ET-1) in human hepatic circulation.
  • To determine the correlation between these molecules and hepatic blood flow in patients with liver conditions.

Main Methods:

  • Studied 27 patients with liver tumors, including those with cirrhosis and chronic hepatitis.
  • Measured portal vein and hepatic arterial blood flow using an electromagnetic flowmeter.
  • Quantitated ET-1 and nitrate/nitrite (NOx) levels in portal, peripheral venous, and arterial blood samples.

Main Results:

  • Serum ET-1 levels were higher in patients with liver cirrhosis.
  • Portal blood flow and estimated total hepatic blood flow were inversely correlated with portal vein ET-1.
  • The ratio of NOx to ET-1 in portal veins correlated better with portal and hepatic blood flow than ET-1 or NOx alone.

Conclusions:

  • Portal ET-1 levels are significantly associated with portal and total hepatic blood flow in humans.
  • The NOx to ET-1 ratio serves as a superior indicator of hepatic hemodynamics compared to individual measurements.
  • Findings contribute to understanding human hepatic hemodynamics, despite clinical setting limitations.
Abstract

More Related Videos

Monitoring of Systemic and Hepatic Hemodynamic Parameters in Mice16:09

Monitoring of Systemic and Hepatic Hemodynamic Parameters in Mice

Published on: October 4, 2014

An All-Human Hepatic Culture System for Drug Development Applications07:23

An All-Human Hepatic Culture System for Drug Development Applications

Published on: October 20, 2023

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Hepatic Drug Clearance: Effect of Protein Binding01:09

Hepatic Drug Clearance: Effect of Protein Binding

Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
Hepatic Drug Clearance: Restrictive and Nonrestrictive Clearance01:09

Hepatic Drug Clearance: Restrictive and Nonrestrictive Clearance

Hepatic clearance refers to the volume of blood cleared of a drug by the liver per unit of time. It plays a crucial role in drug metabolism and elimination. While hepatic clearance is commonly estimated by subtracting renal clearance from total body clearance, other pathways, such as pulmonary or biliary clearance, may also contribute. However, these pathways are generally less significant than hepatic and renal clearance.
Most drugs undergo restrictive clearance, which is proportional to the...
Hepatic Drug Excretion: Enterohepatic Cycling01:17

Hepatic Drug Excretion: Enterohepatic Cycling

Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...